What Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Sell
28
IRWD Quote, Financials, Valuation and Earnings
Last price:
$0.66
Seasonality move
:
-0.86%
Day range:
$0.68 - $0.76
52-week range:
$0.59 - $7.11
Dividend yield:
0%
P/E ratio:
126.50x
P/S ratio:
0.35x
P/B ratio:
--
Volume:
2.1M
Avg. volume:
3.6M
1-year change:
-89.77%
Market cap:
$110.7M
Revenue:
$351.4M
EPS (TTM):
-$0.20
Analysts' Opinion
-
Consensus RatingIronwood Pharmaceuticals has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $0.95, Ironwood Pharmaceuticals has an estimated upside of 38.85% from its current price of $0.68.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.70 representing 100% downside risk from its current price of $0.68.
Fair Value
-
According to the consensus of 4 analysts, Ironwood Pharmaceuticals has 38.85% upside to fair value with a price target of $0.95 per share.
IRWD vs. S&P 500
-
Over the past 5 trading days, Ironwood Pharmaceuticals has underperformed the S&P 500 by -28.98% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ironwood Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ironwood Pharmaceuticals revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Ironwood Pharmaceuticals reported revenues of $41.1M.
Earnings Growth
-
Ironwood Pharmaceuticals earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Ironwood Pharmaceuticals reported earnings per share of -$0.23.
Enterprise value:
586.4M
EV / Invested capital:
2.34x
Price / LTM sales:
0.35x
EV / EBIT:
10.17x
EV / Revenue:
1.85x
PEG ratio (5yr expected):
--
EV / Free cash flow:
7.48x
Price / Operating cash flow:
1.41x
Enterprise value / EBITDA:
9.83x
Gross Profit (TTM):
--
Return On Assets:
-8.5%
Net Income Margin (TTM):
-10.18%
Return On Equity:
--
Return On Invested Capital:
-11.04%
Operating Margin:
-25.64%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $417.1M | $413.6M | $317.7M | $74.9M | $41.1M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | $252.6M | $119.7M | $73.7M | $11.5M | -$10.5M | |
| EBITDA | $270.1M | -$980.2M | $59.6M | $12.3M | -$27.9M | |
| Diluted EPS | $1.01 | -$6.79 | -$0.20 | -$0.03 | -$0.23 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $538.2M | $710.1M | $866.4M | $208.2M | $160.6M | |
| Total Assets | $599.3M | $1.1B | $1.2B | $438.8M | $327.2M | |
| Current Liabilities | $23.6M | $147.4M | $23.8M | $252.4M | $48.1M | |
| Total Liabilities | $489.2M | $565.6M | $448.4M | $769.3M | $661.3M | |
| Total Equity | $110.2M | $517.8M | $706.9M | -$330.5M | -$334.1M | |
| Total Debt | $436.1M | $515.6M | $396.7M | $673.3M | $584.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $289.8M | $148.2M | $78.5M | $45M | $20M | |
| Cash From Investing | -$140K | -$1B | -$105K | -$68K | -$31K | |
| Cash From Financing | -$142.7M | $257.6M | -$91.4M | -$15.6M | $6K | |
| Free Cash Flow | $289.7M | $147.9M | $78.4M | $44.9M | $19.9M | |
IRWD
Sector
Market Cap
$110.7M
$34.6M
Price % of 52-Week High
9.63%
43.69%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.59%
1-Year Price Total Return
-89.77%
-41.18%
Beta (5-Year)
0.369
0.659
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.80
200-day SMA
Sell
Level
$3.34
Bollinger Bands (100)
Sell
Level
0.88 - 3.46
Chaikin Money Flow
Buy
Level
3.1M
20-day SMA
Sell
Level
$0.82
Relative Strength Index (RSI14)
Sell
Level
30.40
ADX Line
Sell
Level
37.78
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$1.15
MACD (12, 26)
Sell
Level
-0.13
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Sell
Level
-28.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.7045)
Sell
CA Score
(Annual)
Level (-4.965)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Buy
Ohlson Score
Level (-585.3718)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.
Stock Forecast FAQ
In the current month, IRWD has received 0 Buy ratings 4 Hold ratings, and 0 Sell ratings. The IRWD average analyst price target in the past 3 months is $0.95.
-
Where Will Ironwood Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ironwood Pharmaceuticals share price will rise to $0.95 per share over the next 12 months.
-
What Do Analysts Say About Ironwood Pharmaceuticals?
Analysts are divided on their view about Ironwood Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ironwood Pharmaceuticals is a Sell and believe this share price will drop from its current level to $0.70.
-
What Is Ironwood Pharmaceuticals's Price Target?
The price target for Ironwood Pharmaceuticals over the next 1-year time period is forecast to be $0.95 according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is IRWD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ironwood Pharmaceuticals is a Hold. 4 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of IRWD?
You can purchase shares of Ironwood Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ironwood Pharmaceuticals shares.
-
What Is The Ironwood Pharmaceuticals Share Price Today?
Ironwood Pharmaceuticals was last trading at $0.66 per share. This represents the most recent stock quote for Ironwood Pharmaceuticals. Yesterday, Ironwood Pharmaceuticals closed at $0.68 per share.
-
How To Buy Ironwood Pharmaceuticals Stock Online?
In order to purchase Ironwood Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Which Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Is Gartner a Safe Stock to Own?
Gartner (NYSE:IT) is among the world’s largest consulting, research and…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 44x
Alerts
Buy
57
RGC alert for May 14
Regencell Bioscience Holdings [RGC] is up 8.9% over the past day.
Buy
54
HALO alert for May 14
Halozyme Therapeutics [HALO] is down 4.72% over the past day.
Buy
91
COIN alert for May 14
Coinbase Global [COIN] is up 2.36% over the past day.
